On May 24, 2010
Wyeth Targeted “High Risk” Black Patients for Off-Label Kidney Drug Sales, Suit Claims
Everyone knows that drug companies sometimes step over the line and market their drugs for unapproved or “off-label” purposes, but drug sales reps at Wyeth (later acquired by Pfizer (PFE)) allegedly combined that taboo with another — targeting vulnerable black
…
0 Comments